Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer

HIPEC is offered to patients with ovarian, fallopian tube or primary peritoneal cancer at some hospitals. Altogether, there is still no evidence that HIPEC leads to an improvement of prognosis in any gynecologic tumor, neither in primary therapy nor in treatment of relapse. The available data indica...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Harter, P., Mahner, S., Hilpert, F., Runnebaum, I., Ortmann, O., Mustea, A., Sehouli, J., du Bois, A., Wagner, U.
Format: Artigo
Langue:Inglês
Publié: Georg Thieme Verlag KG 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3964375/
https://ncbi.nlm.nih.gov/pubmed/24771913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0032-1328320
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires